FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4226002956> ?p ?o ?g. }

• W4226002956 endingPage "547" @default.
• W4226002956 startingPage "538" @default.
• W4226002956 abstract "The management of breast cancer brain metastases (BCBM) has historically involved local therapies. However, as novel systemic treatments have become more effective in controlling visceral disease, BCBM have also been better controlled. Immune checkpoint inhibitors (ICIs) have demonstrated efficacy in brain metastases in patients with lung cancer and melanoma and represent a promising option for patients with triple-negative BCBM, a group with limited systemic therapy options. In this review we summarize current data about the role of ICIs in the treatment BCBM. We identified 15 clinical trials that evaluated ICIs ± chemotherapy in patients with breast cancer. The studies were mostly focused on triple-negative breast cancer (TNBC). Of these trials, 4 excluded patients with BCBM, while 11 allowed patients with stable, treated or asymptomatic BCBM. In total, 2692 patients were enrolled in the identified clinical trials, but only 91 trial patients (3.3%) had BCBM. Furthermore, only 2 of these clinical trials reported BCBM-specific outcomes and none of the clinical trials reported BCBM-specific adverse events. Up to 45% of patients with TNBC will develop BCBM; however, only 3.3% of the patients included in the clinical trials that led to the U.S. Food and Drug Administration approvals for ICIs in advanced breast cancer had brain metastases. This review reinforces that efficacy data are greatly needed for patients with BCBM-this is an area of unmet need in oncology. More inclusive clinical trials and real-world data that evaluate the safety and efficacy of ICIs in patients with BCBM are greatly needed." @default.
• W4226002956 created "2022-05-05" @default.
• W4226002956 creator A5022515427 @default.
• W4226002956 creator A5037671574 @default.
• W4226002956 date "2022-05-22" @default.
• W4226002956 modified "2023-09-26" @default.
• W4226002956 title "Immune Checkpoint Inhibitors in the Treatment of Breast Cancer Brain Metastases" @default.
• W4226002956 cites W179889400 @default.
• W4226002956 cites W1918237073 @default.
• W4226002956 cites W1966999467 @default.
• W4226002956 cites W1980200619 @default.
• W4226002956 cites W1987577775 @default.
• W4226002956 cites W1992137963 @default.
• W4226002956 cites W2000798782 @default.
• W4226002956 cites W2000837172 @default.
• W4226002956 cites W2009776759 @default.
• W4226002956 cites W2015944208 @default.
• W4226002956 cites W2015996473 @default.
• W4226002956 cites W2016908822 @default.
• W4226002956 cites W2026266923 @default.
• W4226002956 cites W2032861264 @default.
• W4226002956 cites W2035570331 @default.
• W4226002956 cites W2037873158 @default.
• W4226002956 cites W2072561192 @default.
• W4226002956 cites W2088993386 @default.
• W4226002956 cites W2103220202 @default.
• W4226002956 cites W2127199535 @default.
• W4226002956 cites W2128871519 @default.
• W4226002956 cites W2129749518 @default.
• W4226002956 cites W2130735457 @default.
• W4226002956 cites W2134878729 @default.
• W4226002956 cites W2141393790 @default.
• W4226002956 cites W2152061559 @default.
• W4226002956 cites W2155073814 @default.
• W4226002956 cites W2158789700 @default.
• W4226002956 cites W2159821105 @default.
• W4226002956 cites W2162887147 @default.
• W4226002956 cites W2168167705 @default.
• W4226002956 cites W2168814163 @default.
• W4226002956 cites W2171481006 @default.
• W4226002956 cites W2177244913 @default.
• W4226002956 cites W2236375555 @default.
• W4226002956 cites W2292383635 @default.
• W4226002956 cites W2329793926 @default.
• W4226002956 cites W2343844322 @default.
• W4226002956 cites W2345415641 @default.
• W4226002956 cites W2416791964 @default.
• W4226002956 cites W2514622968 @default.
• W4226002956 cites W2527905628 @default.
• W4226002956 cites W2528962190 @default.
• W4226002956 cites W2560367415 @default.
• W4226002956 cites W2560704457 @default.
• W4226002956 cites W2584244467 @default.
• W4226002956 cites W2595711623 @default.
• W4226002956 cites W2608436322 @default.
• W4226002956 cites W2743518140 @default.
• W4226002956 cites W2765625354 @default.
• W4226002956 cites W2766673799 @default.
• W4226002956 cites W2786709615 @default.
• W4226002956 cites W2791308824 @default.
• W4226002956 cites W2794627893 @default.
• W4226002956 cites W2796582438 @default.
• W4226002956 cites W2801309958 @default.
• W4226002956 cites W2803551341 @default.
• W4226002956 cites W2805634179 @default.
• W4226002956 cites W2887919639 @default.
• W4226002956 cites W2888298425 @default.
• W4226002956 cites W2889746019 @default.
• W4226002956 cites W2890298773 @default.
• W4226002956 cites W2897422388 @default.
• W4226002956 cites W2897523860 @default.
• W4226002956 cites W2900126305 @default.
• W4226002956 cites W2902530914 @default.
• W4226002956 cites W2902655481 @default.
• W4226002956 cites W2905870269 @default.
• W4226002956 cites W2908622615 @default.
• W4226002956 cites W2914643394 @default.
• W4226002956 cites W2917403028 @default.
• W4226002956 cites W2923848698 @default.
• W4226002956 cites W2946779032 @default.
• W4226002956 cites W2946839540 @default.
• W4226002956 cites W2953287793 @default.
• W4226002956 cites W2965909282 @default.
• W4226002956 cites W2980385048 @default.
• W4226002956 cites W2980525484 @default.
• W4226002956 cites W2990398119 @default.
• W4226002956 cites W2995808512 @default.
• W4226002956 cites W2997096971 @default.
• W4226002956 cites W2998015460 @default.
• W4226002956 cites W2999417355 @default.
• W4226002956 cites W3014209163 @default.
• W4226002956 cites W3030461309 @default.
• W4226002956 cites W3039853672 @default.
• W4226002956 cites W3047848114 @default.
• W4226002956 cites W3081659024 @default.
• W4226002956 cites W3091904852 @default.
• W4226002956 cites W3105137750 @default.
• W4226002956 cites W3109853980 @default.

• next